Insider Selling: Flexion Therapeutics Inc (FLXN) Insider Sells 5,000 Shares of Stock

Flexion Therapeutics Inc (NASDAQ:FLXN) insider Neil Bodick sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $20.41, for a total value of $102,050.00. Following the transaction, the insider now directly owns 50,937 shares in the company, valued at $1,039,624.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Neil Bodick also recently made the following trade(s):

  • On Friday, February 24th, Neil Bodick sold 5,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $19.15, for a total value of $95,750.00.
  • On Friday, January 20th, Neil Bodick sold 5,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $18.35, for a total value of $91,750.00.
  • On Wednesday, December 21st, Neil Bodick sold 10,000 shares of Flexion Therapeutics stock. The shares were sold at an average price of $18.46, for a total value of $184,600.00.

Flexion Therapeutics Inc (NASDAQ:FLXN) traded up 2.67% during mid-day trading on Monday, hitting $20.80. 147,961 shares of the stock were exchanged. The firm’s market capitalization is $660.00 million. The company’s 50-day moving average price is $19.73 and its 200 day moving average price is $18.95. Flexion Therapeutics Inc has a 52 week low of $7.68 and a 52 week high of $23.57.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.08. Equities research analysts expect that Flexion Therapeutics Inc will post ($3.46) EPS for the current year.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Your IP Address:

A number of research firms have recently weighed in on FLXN. Cantor Fitzgerald set a $37.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, December 12th. BMO Capital Markets reiterated an “outperform” rating and set a $33.00 target price on shares of Flexion Therapeutics in a report on Thursday, December 15th. Janney Montgomery Scott reiterated a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Raymond James Financial, Inc. began coverage on shares of Flexion Therapeutics in a report on Thursday, December 22nd. They set a “strong-buy” rating and a $35.00 target price for the company. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Flexion Therapeutics has a consensus rating of “Buy” and an average target price of $28.55.

A number of hedge funds have recently made changes to their positions in the company. Keybank National Association OH boosted its stake in shares of Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 67 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 0.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 52,850 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after buying an additional 450 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 15.8% in the third quarter. Alps Advisors Inc. now owns 35,084 shares of the specialty pharmaceutical company’s stock valued at $686,000 after buying an additional 4,783 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Flexion Therapeutics by 6.3% in the third quarter. JPMorgan Chase & Co. now owns 119,050 shares of the specialty pharmaceutical company’s stock valued at $2,326,000 after buying an additional 7,075 shares during the last quarter. Finally, SECOR Capital Advisors LP bought a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $214,000. Institutional investors and hedge funds own 62.25% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

5 Day Chart for NASDAQ:FLXN

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024233/insider-selling-flexion-therapeutics-inc-flxn-insider-sells-5000-shares-of-stock.html

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.